Sagimet Biosciences Inc
SGMT
NASDAQ
Biotechnology
$10.55
USD
+1.27 (+13.69%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $567.79M
Volume 2.7M
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-47.08M
TTM
+20.7%
YoY
Operating Cash Flow
$-41.72M
TTM
+23.1%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 4.7 | 4.6 | 4.0 | 4.7 | 4.3 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 11.9 | 14.3 | 10.8 | 11.7 | 15.8 |
Operating Income | -11.9 | -14.3 | -10.8 | -11.7 | -15.8 |
EBITDA | -11.9 | -14.3 | -10.8 | -11.7 | -15.8 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 1.5 | 1.4 | 1.2 | 1.1 | 1.9 |
Income Before Income Taxes | -10.4 | -12.9 | -9.6 | -10.7 | -14.0 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -10.4 | -12.9 | -9.6 | -10.7 | -14.0 |
Consolidated Net Income / Loss | -10.4 | -12.9 | -9.6 | -10.7 | -14.0 |
Net Income Attributable to Common Shareholders | -10.4 | -12.9 | -9.6 | -10.7 | -14.0 |
Basic EPS | -$0.32 | -$0.40 | -$0.29 | -$0.33 | -$0.26 |
Diluted EPS | -$0.32 | -$0.40 | -$0.29 | -$0.33 | -$0.26 |
Basic Shares Outstanding | 32.2M | 32.5M | 32.5M | 32.6M | 53.1M |
Diluted Shares Outstanding | 32.2M | 32.5M | 32.5M | 32.6M | 53.1M |